Author Archive: Jeremy Parkinson
The Acronym Of 2008 Is Sounding Another Alarm
LIBOR, or the London Interbank Offered Rate, was the most important acronym most investors never heard of before 2008. However, it quickly became the most critical variable in markets leading up to the Great Recession. What has now become clear is that we haven’t learned any lessons from the financial crisis except how to accumulate […]
Cracked Diamond
Hmmm. Things are looking less sanguine in bear-land. Although the SPY gap is still firmly intact, and has plenty of cushion left: The Dow Industrials DIA has broken its descending trendline and exceeded its gap. Worrisome!
Comments On The S&P And USD
(Audio length 00:10:49) Doc joins me today to shares his thoughts on the US markets and the USD. With daily volatility but no major breakouts in either direction, there are some levels we expect before the next bigger move. For the USD it continues to look weak but trade in a tighter range. Sounds like […]
Trump Halts Plan For More Russia Sanctions; Russian Stocks, Ruble Jump
What would’ve been the second round of economic sanctions levied at Moscow since the poisoning of former Russian spy Sergei Skripal has been walked back by the White House, which apparently has put its latest round of sanction plans “in a holding pattern” following a coordinated missile strike in Syria late Friday. The sanctions were […]
Palladium Rally Driving Other Metals Moves?
Many months ago we made an interesting call in Palladium and alerted to this setup on January 24th, 2018. This nearly perfect call included our future price expectations using our advanced ADL price modeling system. Today, we are refreshing that call with a new market call to inform you that our price prediction has played out […]
Blueprint Sinks, Loxo Rises After Trial Data On Potential Solid Tumor Treatment
Shares of Blueprint Medicines (BPMC) are sliding after the company reported data over the weekend regarding its early-stage candidate in RET-altered tumors. This morning, both Wedbush and JMP Securities raised their price targets on the stock, while Morgan Stanley analyst Matthew Harrison upgraded competitor Loxo Oncology (LOXO) to a buy-equivalent rating as he believes the […]
February 2018 Headline Business Sales Declined, Inventories Grew
Econintersect‘s analysis of final business sales data (retail plus wholesale plus manufacturing) shows a slowing in the rate of growth. Inventory levels are very high and do not correlate to times of economic expansion. Analyst Opinion of Business Sales and Inventories Inventories remain elevated this month. Our primary monitoring tool – the 3 month rolling […]
Weekly Technical Perspective On NZD/USD, GBP/USD And EUR/NZD
In this series, we scale-back and take a look at the broader technical picture to gain a bit more perspective on where we are in trend. Here are the key levels that matter on the weekly charts for the NZD/USD, GBP/USD and EUR/NZD. NZD/USD WEEKLY PRICE CHART Notes: Last month we noted that the New Zealand Dollar had,“continued […]
Tesla’s Storm Clouds
Just to make sure you don’t miss it,please note there is an open plea for people to test the new site, so please read the post if you didn’t. Over the long haul, there’s no arguing that Tesla has been anything but an incredible stock, having moved up many, many hundreds of percent: Shorter-term, however, things are […]
Trader: ‘Investors Know Central Banks Are Just As Deeply Into These Trades As They Are’
Remember what I said last night? No? That’s ok, I wouldn’t either were it not for the unfortunate circumstances that forced me to give up Balvenie forever. But for those who are still free to imbibe and thus perhaps prone to forgetting what was and wasn’t said on Saturday and Sunday evenings, here was our assessment of […]
